News & Updates
Filter by Specialty:
Dostarlimab-chemo a new SoC for endometrial cancer?
In the second interim analysis of part 1 of the phase III ENGOT-EN6-NSGO/GOG-3031/RUBY trial, dostarlimab plus carboplatin/paclitaxel (CP) chemotherapy delivered a significant survival benefit in women with primary advanced or recurrent endometrial cancer.
Dostarlimab-chemo a new SoC for endometrial cancer?
02 May 2024
Improved cervical screening uptake among local South Asian women following CUHK training
Expansion of a territory-wide cervical screening programme to train a group of local South Asian women has enabled education regarding cervical cancer and screening services among their peers, and considerably improved screening uptake.
Improved cervical screening uptake among local South Asian women following CUHK training
01 May 2024
ALK+ NSCLC: Real-world patterns and outcomes of treatment after 1L brigatinib
Following first-line (1L) brigatinib treatment, most patients with ALK-positive (ALK+) non-small-cell lung cancer (NSCLC) received an ALK tyrosine kinase inhibitor (TKI) as second-line (2L) therapy and experienced prolonged clinical benefit, a retrospective chart review of patients enrolled in the phase III ALTA-1L trial has shown.
ALK+ NSCLC: Real-world patterns and outcomes of treatment after 1L brigatinib
30 Apr 2024
Switching from cetuximab to bevacizumab associated with acceptable survival, reduced derm toxicity in mCRC
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab leads to acceptable survival outcomes and a reduction in severe dermatological toxicities in patients with RAS wild-type (RASwt) metastatic colorectal cancer (mCRC), according to the results of a single-arm phase II HYBRID trial.
